COVID-19

Data on excess deaths in high-income countries show the male mortality disadvantage during COVID-19 is concentrated in the pandemic's earliest phase.

A target trial emulation found early remdesivir initiation was associated with reduced 1-year risk of graft loss and cardiovascular events.

As COVID-19 shifts from emergency response to routine care, persistent inequities in vaccine access are quietly resurfacing.

Bivalent mRNA and protein-based fourth doses produce comparable protection against Omicron JN.1 infection over 12 months.

Investigators test 3 repurposed drugs alongside specialist care, finding small, transient fatigue improvements for long COVID fatigue.

CDC-led VISION interim data show 2025-2026 COVID-19 shots cut adult emergency room visits and hospitalizations.

Researchers explore how the prevalence, duration, and characteristics of post-COVID-19 symptoms varied by epidemic period.

Among patients using corticosteroids during hospital stays, researchers assess patient-reported symptoms of long COVID during follow-up.

Coadministering COVID-19 and influenza vaccines did not raise the 90-day risk of serious or clinically meaningful adverse events.

The ACTIV-6 trial suggests early metformin may halve clinician-diagnosed long COVID risk, offering a low-cost option pharmacists can apply safely.

BA.3.2 variant spreads globally, testing vaccine matches as the FDA backs XFG immunizations.

The approval arrives prior to the Prescription Drug User Fee Act action date of June 16, 2026.

Oral ensitrelvir given within 72 hours cuts household symptomatic COVID-19 by 67%, showing safe postexposure prevention.

A head-to-head trial shows a protein-based COVID-19 booster causes fewer adverse effects, boosting patient preference and aiding pharmacists.

With the federal government continuing its reconsideration of vaccine guidelines in the US, Jeff Goad, PharmD, MPH, explains what it means for community pharmacies.

Jeff Goad, PharmD, MPH, joins Drug Topics to discuss potential COVID-19 vaccine removal and what it could mean for the future of mRNA vaccine technology.

Marking 5 years since the COVID-19 pandemic forever changed health care in 2020, check out the top 5 COVID-19 stories from 2025.

A recent study reveals COVID-19 vaccination significantly reduces severe maternal disease and preterm birth risks during pregnancy.

The Sinovac-CoronaVac vaccine significantly reduces COVID-19 mortality in patients with schizophrenia, highlighting an increased importance of vaccination.

Investigators analyze bureaucratic hurdles in multicountry COVID-19 trials, revealing delays that hinder timely evidence for treatment guidelines.

Among patients previously reporting COVID-19, researchers conduct a case-control study of REM-predominant obstructive sleep apnea.

The agency’s findings spur promises of significant change to the development and recommendations surrounding various immunizations.

After nearly 20 years of pneumococcal conjugate vaccine use in the Portuguese vaccine schedule, researchers explore serotype distribution in bacteria causing adult invasive pneumococcal disease (IPD).

A study reveals declining support for COVID-19 measures over time, highlighting the critical role of pharmacists in providing essential health education.

A study reveals first-trimester SARS-CoV-2 infection increases neonatal risks and highlights disparities in testing among pregnant women across demographics.